Last updated: May 4, 2026
CARTIA XT (diltiazem hydrochloride extended-release): Clinical Trial Update, Market Analysis, and Projection
What is CARTIA XT and where does it sit therapeutically?
CARTIA XT is an extended-release formulation of diltiazem hydrochloride for the treatment of hypertension and angina. It is a branded product marketed in the U.S. under a New Drug Application history that supports the brand’s long-standing presence, with competitive pressure from generics and other branded extended-release diltiazem products.
Active ingredient: diltiazem hydrochloride (extended-release)
Core indications: hypertension; angina (as listed in product labeling and drug monographs)
Therapeutic class: calcium channel blocker (non-dihydropyridine)
For clinical-trial monitoring and market modeling, CARTIA XT should be tracked under diltiazem ER rather than as an isolated molecule, because most late-stage clinical activity for diltiazem is sparse and product-level differentiation is typically driven by formulation and bioequivalence rather than new mechanism.
What do the clinical trials and regulatory filings show for CARTIA XT specifically?
No current, active, pivotal Phase 2/3 clinical program unique to CARTIA XT has been identified from public trial registries in the sources cited below. Public registries primarily show diltiazem in older cardiovascular contexts and do not consistently tie trials to the CARTIA XT brand.
Practical implication for R&D calendars: CARTIA XT is best treated as an off-patent, mature product where near-term value capture depends on:
- Formulation lifecycle management (bioequivalence maintenance, supply, packaging)
- Switching dynamics between brand and generics
- Payor contracting and tendering behavior for chronic CCB therapy
Clinical evidence base: diltiazem ER has an established clinical literature profile, and the ongoing competitive landscape is more influenced by generic entry and substitution than by new clinical efficacy trials for the brand.
What does the market look like for diltiazem ER and branded CARTIA XT?
CARTIA XT competes in a crowded, cost-sensitive cardiovascular market. Key market mechanics:
-
Generic substitution pressure
- Diltiazem ER is widely genericized across multiple strengths and dosing regimens.
- Branded sales typically decline after loss of exclusivity and face persistent price compression.
-
Class competition
- Other oral antihypertensives and antianginal agents compete for formularies, including other CCBs, ACE inhibitors/ARBs, beta-blockers, diuretics, and fixed combinations.
- For angina, product selection also reflects provider preference and patient tolerability.
-
Pharmacy benefit design
- Health plans commonly apply tiering that accelerates switching to the lowest net-cost option.
- Even where a branded ER diltiazem remains covered, pharmacy copay structures can drive brand-to-generic migration.
What sources support market-state framing
- FDA’s Orange Book is the canonical location for exclusivity and listed patents for the specific active ingredient and dosage form, enabling product-by-product exclusivity mapping. [1]
- FDA’s drug shortages database is relevant for whether supply constraints could transiently protect a brand, but it is not an ongoing clinical differentiator. [2]
- IMS-like volume models are not embedded in the cited sources below; the analysis here uses the regulatory and substitution framework to anchor projections rather than quoting unsupported proprietary market sizing.
Are there supply, safety, or regulatory events that can move sales for CARTIA XT?
CARTIA XT demand can be affected by two observable vectors:
- Drug shortages / manufacturing constraints (brand protection during constrained supply)
- Regulatory listing changes (Orange Book updates) that can signal new patent/expiry events or the approach of generic entry
The primary check points for investors and commercial planners are:
- Orange Book status by strength and dosage form for listed patents and exclusivity windows. [1]
- FDA shortage notifications for diltiazem ER products that could affect availability. [2]
How should investors project CARTIA XT revenue and volume going forward?
Because CARTIA XT is an established ER diltiazem brand competing in a genericized market, projections should be structured as a declining branded share with sensitivity to payor contracts, generic supply stability, and any shortage-driven temporary uplift.
A practical projection framework (used for mature cardiovascular brands) is:
1) Baseline trajectory: branded erosion
- Branded units typically trend downward as formularies favor generics.
- The magnitude depends on net price and plan coverage status.
2) Short-term upside scenarios
- Shortages affecting generic supply can temporarily lift branded share.
- Contracting decisions can delay or accelerate share loss.
3) Long-term trajectory
- Absent a new patent life extension or differentiation that compels payor preference, the long-run pattern is steady share compression toward the least-cost option.
4) Key sensitivity drivers to model
- Net price trend (rebates, wholesaler chargebacks, contract changes)
- Formulary tier position (preferred vs non-preferred)
- Generic availability (manufacturing continuity; FDA shortage events)
- Patient persistence in chronic CCB therapy (reducing churn once stable, but still vulnerable to substitution)
These drivers tie directly to observable regulatory and operational datasets: Orange Book patent listing state [1] and FDA shortages [2].
What patent and exclusivity signals matter for CARTIA XT?
For brand value protection, the decisive inputs are the Orange Book patent listings and exclusivity status for the exact branded product/dosage forms.
Actionable monitoring workflow
- Track Orange Book listings for:
- Listed patents by number
- Expiration dates
- Exclusivity claims
- Monitor for:
- Patent delistings or amendments
- New patent additions
- Launch signals from ANDA approvals or Para IV outcomes (where public)
This is the most defensible public method for mapping the legal timeline behind branded erosion. [1]
Is there any evidence of active development that could re-accelerate CARTIA XT demand?
Based on the public trial record emphasis in the cited sources, CARTIA XT itself does not appear to have a fresh, brand-specific late-stage clinical pipeline driving new labeling or differentiation. The likely near-term plan remains commercial lifecycle management, not clinical re-invention.
Clinical development impact is therefore limited to:
- New guideline positioning that affects class-level prescribing
- Safety communications that affect use
- Supply disruptions that temporarily shift substitution patterns
Safety and label baseline checks are driven by labeling sources, such as FDA label content and structured drug references. [3]
Market Projection Table (Structure for Investment Use)
The table below translates the mechanics into a model shape for branded CARTIA XT. It does not assume unsupported market sizing; it provides a defensible projection pattern given typical mature branded-to-generic substitution dynamics.
| Driver |
Effect on CARTIA XT branded sales |
Modeling direction |
| Generic substitution |
Reduces branded share and volume |
Downward with time |
| Payor tiering |
Decreases brand access or increases copays |
Downward unless contract improves |
| Net price compression |
Reduces revenue per unit |
Downward even if units stabilize |
| Generic supply continuity |
Maintains substitution pressure without uplift |
Neutral to downward |
| FDA drug shortages (any supply disruption) |
Can temporarily lift brand share |
Upside shocks (short duration) |
| Label/safety communications |
Could change prescribing behavior |
Secondary; usually modest |
Sources that anchor the structural monitoring inputs: Orange Book for exclusivity and patent timeline [1]; FDA shortages for supply shocks [2]; FDA labeling for indications and baseline product characterization [3].
Key Takeaways
- CARTIA XT is a mature branded diltiazem ER product competing in a genericized cardiovascular market where sales are primarily shaped by substitution, payor contracting, and supply stability rather than new clinical differentiation.
- Public clinical trial activity does not point to a brand-specific, late-stage pipeline that would justify a demand reset in the near term.
- Investment-grade projection should model steady branded share erosion, with sensitivity to FDA shortage events and formulary tier changes.
- Patent and exclusivity monitoring should use the FDA Orange Book for product-specific listing status by strength and dosage form. [1]
FAQs
1) What is the active ingredient in CARTIA XT?
CARTIA XT contains diltiazem hydrochloride in an extended-release formulation. [3]
2) What conditions is CARTIA XT indicated for?
CARTIA XT is indicated for hypertension and angina, consistent with FDA label content and drug references. [3]
3) Are there current brand-specific Phase 2/3 clinical trials driving CARTIA XT growth?
Publicly available registry and labeling-based sources cited here do not indicate an ongoing, brand-unique late-stage program. The brand’s competitive position is therefore driven more by lifecycle and access dynamics than by new clinical trials. [1][3]
4) What data should be monitored to assess supply-driven sales swings?
Use FDA drug shortage notifications for relevant diltiazem ER products to detect transient disruptions that can shift substitution patterns. [2]
5) Where can investors check patent and exclusivity status for CARTIA XT?
The FDA Orange Book provides the authoritative listing of patents and exclusivity tied to the approved product(s). [1]
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
[2] U.S. Food and Drug Administration. (n.d.). Drug Shortages. https://www.fda.gov/drugs/drug-shortages
[3] U.S. Food and Drug Administration. (n.d.). Labeling for CARTIA XT (diltiazem hydrochloride extended-release). https://www.accessdata.fda.gov/scripts/cder/daf/
